← Eichor
Study identifier: NCT06712108 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Double Unit Cord Blood Transplant in Hematologic Malignancies.

Condition: Adult Double Unit Cord Blood Transplant  ·  Sponsor: Seoul National University Hospital

PhaseN/A
Planned participants40
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

The efficacy and safety of non-myeloablative and myeloablative preconditioning followed by dual-unit umbilical cord blood transplantation from unrelated donors in adult patients with malignant hematologic diseases eligible for allogeneic hematopoietic stem cell transplantation are evaluated through prospective observation and analysis of actual clinical data collection

This description comes directly from the study's public registry record.

Talk to the study team

Dong-Yeop Shin, MD, PhD.  ·  +82-2-2072-7209  ·  shindongyeop@snu.ac.kr

Always discuss trial participation with your own doctor first.

Locations (6)

Jeonbuk National University HopitalJeonju, Jeonlabuk-do, South KoreaNot Yet Recruiting
Keimyung Unversity Dongsan HospitalDaegu, South KoreaNot Yet Recruiting
Dong-A University HospitalPusan, South KoreaNot Yet Recruiting
Pusan National University HospitalPusan, South KoreaNot Yet Recruiting
Seoul National University Bundang HospitalSeongnam, South KoreaNot Yet Recruiting
Seoul National University HospitalSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06712108